SIGY
Sigyn Therapeutics, Inc. operates as a development-stage therapeutic technology company. It offers Sigyn Therapy, a blood purification technology to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the cause of hospital deaths. The company also engages in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; CytoVesicles; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. The company is headquartered in San Diego, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q3 | -0.36 | $0 | -$199,326 |
| 2025 Q2 | -0.90 | $0 | -$152,436 |
| 2025 Q1 | -0.42 | $0 | -$294,446 |
| 2024 Q4 | -0.33 | $5,774 | -$290,218 |
| 2024 Q3 | -0.94 | $0 | -$163,816 |
| 2024 Q2 | -0.70 | $0 | -$182,790 |
| 2024 Q1 | -0.62 | $0 | -$235,612 |
| 2023 Q4 | -0.94 | $14,492 | -$127,894 |